Literature DB >> 12904890

Development of humanized mice as a model of inflammatory arthritis.

Grete Sønderstrup1.   

Abstract

Clinically, rheumatoid arthritis (RA) is a chronic deforming disease characterized mainly by joint swelling and destruction. Although synovial inflammation and bone erosion are the hallmarks of this disease, the presentation of various features between patients is clearly heterogenous, suggesting that there are different variants of RA. Hence, the development of an animal model that has all of the elements of human RA has remained elusive. This review explores several different views on the etiology of RA and the recent data from various murine arthritis models which provide support for these theories. In addition to discussing the potential roles of CD4(+) T cell activation, autoantibodies, and lymphocyte-independent cytokine production, the role of CD4(+) T regulatory cells will be presented in the context of a newly developed humanized transgenic mouse model. This novel T cell receptor transgenic model is being characterized to enhance our understanding of the mechanisms involved in the breach of self-tolerance that occurs in autoimmune disorders such as RA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12904890     DOI: 10.1007/s00281-003-0129-z

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


  2 in total

1.  Aberrant MHC class II expression in mouse joints leads to arthritis with extraarticular manifestations similar to rheumatoid arthritis.

Authors:  Satoshi Kanazawa; Shusuke Ota; Chiyoko Sekine; Toyohiro Tada; Takanobu Otsuka; Takashi Okamoto; Grete Sønderstrup; B Matija Peterlin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-15       Impact factor: 11.205

Review 2.  Applicability and implementation of the collagen-induced arthritis mouse model, including protocols (Review).

Authors:  Jing Luan; Zhifang Hu; Jianghong Cheng; Ruisan Zhang; Peng Yang; Huifang Guo; Gang Nan; Na Guo; Xingchun Gou
Journal:  Exp Ther Med       Date:  2021-07-01       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.